Unlocking the full potential of GLP-1-based therapy

Eccogene is a clinical stage biopharmaceutical company developing best-in-class small molecule therapeutics for chronic cardiometabolic and inflammatory conditions. Since its founding, the Company has been dedicated to discovering safer and more effective oral therapies that can be used alone or synergistically with a GLP-1 receptor agonist to treat conditions beyond obesity.

Eccogene’s diverse pipeline of small molecule candidates leverages the Company’s world-class expertise in translational research, small molecule discovery, and deep understanding of diabetes, weight loss and cardiometabolic disease pathways. Our oral small molecule GLP-1 receptor agonist, ECC5004, is a potentially best-in-class asset, which we licensed to AstraZeneca. Eccogene also has clinical programs underway that target THR-β and SSAO, as well as preclinical programs targeting proven pathways, such as GIP. The Company’s complementary pipeline fulfills its mission to improve care and expand access to cost effective medicines for millions of patients worldwide who suffer from cardiometabolic and inflammatory diseases.